British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom. Electronic address: https://twitter.com/RyanWereski.
British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom; Department of Medicine, University of Otago, Christchurch, New Zealand.
J Am Coll Cardiol. 2023 Aug 8;82(6):473-485. doi: 10.1016/j.jacc.2023.05.046.
Cardiac troponin is used for risk stratification of patients with acute coronary syndromes; however, the role of testing in other settings remains unclear.
The aim of this study was to evaluate whether cardiac troponin testing could enhance risk stratification in patients with chronic coronary artery disease independent of disease severity and conventional risk measures.
In a prospective cohort of consecutive patients with symptoms suggestive of stable angina attending for outpatient coronary angiography, high-sensitivity cardiac troponin I was measured before angiography, and clinicians were blinded to the results. The primary outcome was myocardial infarction or cardiovascular death during follow-up.
In 4,240 patients (age 66 years [IQR: 59-73 years], 33% female), coronary artery disease was identified in 3,888 (92%) who had 255 (6%) primary outcome events during a median follow-up of 2.4 years (IQR: 1.3-3.6 years). In patients with coronary artery disease, troponin concentrations were 2-fold higher in those with an event compared with those without (6.7 ng/L [IQR: 3.2-14.2 ng/L] vs 3.3 ng/L [IQR: 1.7-6.6 ng/L]; P < 0.001). Troponin concentrations were associated with the primary outcome after adjusting for cardiovascular risk factors and coronary artery disease severity (adjusted HR: 2.3; 95% CI: 1.7-3.0, log troponin; P < 0.001). A troponin concentration >10 ng/L identified patients with a 50% increase in the risk of myocardial infarction or cardiovascular death.
In patients with chronic coronary artery disease, cardiac troponin predicts risk of myocardial infarction or cardiovascular death independent of cardiovascular risk factors and disease severity. Further studies are required to evaluate whether routine testing could inform the selection of high-risk patients for treatment intensification. (Myocardial Injury in Patients Referred for Coronary Angiography [MICA]; ISRCTN15620297).
心肌肌钙蛋白用于急性冠状动脉综合征患者的风险分层;然而,在其他情况下检测的作用尚不清楚。
本研究旨在评估在接受冠状动脉造影的慢性冠状动脉疾病患者中,心肌肌钙蛋白检测是否可以在不考虑疾病严重程度和传统风险因素的情况下增强风险分层。
在连续就诊于门诊行冠状动脉造影的稳定型心绞痛症状患者的前瞻性队列中,在冠状动脉造影前测量高敏心肌肌钙蛋白 I,临床医生对结果设盲。主要结局是随访期间发生心肌梗死或心血管死亡。
在 4240 例患者(年龄 66 岁[IQR:59-73 岁],33%为女性)中,3888 例(92%)存在冠状动脉疾病,其中 255 例(6%)在中位随访 2.4 年(IQR:1.3-3.6 年)期间发生主要结局事件。在患有冠状动脉疾病的患者中,发生事件的患者的肌钙蛋白浓度是未发生事件的患者的两倍(6.7ng/L[IQR:3.2-14.2ng/L]比 3.3ng/L[IQR:1.7-6.6ng/L];P<0.001)。在校正心血管危险因素和冠状动脉疾病严重程度后,肌钙蛋白浓度与主要结局相关(校正 HR:2.3;95%CI:1.7-3.0,对数肌钙蛋白;P<0.001)。肌钙蛋白浓度>10ng/L 可识别出心肌梗死或心血管死亡风险增加 50%的患者。
在慢性冠状动脉疾病患者中,心肌肌钙蛋白预测心肌梗死或心血管死亡的风险独立于心血管危险因素和疾病严重程度。需要进一步研究来评估常规检测是否可以为选择需要强化治疗的高危患者提供信息。(冠状动脉造影患者心肌损伤[MICA];ISRCTN15620297)。